<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10072</article-id><article-id pub-id-type="doi">10.7554/eLife.10072</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>FAK/PYK2 Promotes the Wnt/B-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-28448"><name><surname>Gao</surname><given-names>Chenxi</given-names></name><aff><institution content-type="dept">Department of Pharmacology and Chemical Biology</institution>, <institution>University of Pittsburgh School of Medicine</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-28449"><name><surname>Chen</surname><given-names>Guangming</given-names></name><aff><institution content-type="dept">Department of Pharmacology and Chemical Biology</institution>, <institution>University of Pittsburgh School of Medicine</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38658"><name><surname>Kuan</surname><given-names>Shih-Fan</given-names></name><aff><institution content-type="dept">Department of Pathology</institution>, <institution>University of Pittsburgh School of Medicine</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-28451"><name><surname>Zhang</surname><given-names>Dennis Han</given-names></name><aff><institution>Dietrich School of Arts and Sciences</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15882"><name><surname>Schlaepfer</surname><given-names>David D</given-names></name><aff><institution content-type="dept">Department of Reproductive Medicine, Moores Cancer Center</institution>, <institution>University of California, San Diego</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-27273"><name><surname>Hu</surname><given-names>Jing</given-names></name><aff><institution content-type="dept">Department of Pharmacology and Chemical Biology</institution>, <institution>University of Pittsburgh School of Medicine</institution>, <addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line>, <country>United States</country><email>huj3@upmc.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1062"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Reviewing editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>08</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e10072</elocation-id><history><date date-type="received"><day>14</day><month>07</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Gao et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Gao et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Aberrant activation of Wnt/β-catenin signaling plays an unequivocal role in colorectal cancer, but identification of effective Wnt inhibitors for use in cancer remains a tremendous challenge. New insights into the regulation of this pathway could reveal new therapeutic point of intervention, therefore are greatly needed. Here we report a novel FAK/PYK2/GSK3βY<sup>216</sup>/β-catenin regulation axis: FAK and PYK2, elevated in adenomas in <italic>APC</italic><sup>min/+</sup> mice and in human colorectal cancer tissues, functioned redundantly to promote the Wnt/β-catenin pathway by phosphorylating GSK3β<sup>Y216</sup> to reinforce pathway output-β-catenin accumulation and intestinal tumorigenesis. We previously showed that Wnt-induced β-catenin accumulation requires Wntinduced GSK3β/β-TrCP interaction; the current study revealed that phosphorylation of GSK3β<sup>Y216</sup> was a molecular determinant of GSK3β recruitment of β-TrCP. Pharmacological inhibition of FAK/PYK2 suppressed adenoma formation in <italic>APC</italic><sup>min/+</sup> mice accompanied with reduced intestinal levels of phospho-SK3β<sup>Y216</sup> and β-catenin, indicating that FAK/PYK2/GSK3β<sup>Y216</sup> axis is critical for the activation of Wnt/β-catenin signaling in APCdriven intestinal tumorigenesis.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#14013138) of the University of Pittsburgh.</p></fn></fn-group></back></article>